KELLY NASH: Open Payments
NPI 1568059582 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$360 in 16 payments from 12 companies in 2025. Trend: 2023 $140 · 2024 $139 · 2025 $360
Food & beverage: $360
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $88 |
| AstraZeneca Pharmaceuticals LP | 2 | $49 |
| ARGENX US, INC. | 1 | $31 |
| ABBVIE INC. | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Genentech USA, Inc. | 1 | $25 |
| Celgene Corporation | 1 | $23 |
| Eisai Inc. | 1 | $21 |
| Janssen Biotech, Inc. | 1 | $20 |
| JAZZ PHARMACEUTICALS INC. | 1 | $19 |
Products named: HYQVIA, VONVENDI, LYNPARZA, VYVGART HYTRULO, RUBRACA, ELAHERE, DUPIXENT, Itovebi.
Industry payments across TX — which companies pay providers there.
